# Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States Medical Centers (2011–2016)

# INTRODUCTION

- Community-associated (CA) methicillin-resistant Staphylococcus aureus (CA-MRSA) and health careassociated (HA) MRSA as well as macrolide resistance among  $\beta$ -haemolytic streptococci (BHS) complicate therapy of osteomyelitis and other forms of bone and joint infections (BJI) in children and adults
- Dalbavancin belongs to the lipoglycopeptide class of antimicrobial agents that act by interrupting bacterial cell wall synthesis resulting in bacterial death, and it was approved in the United States (2014) and Europe (2015) to treat adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of S. aureus, including MRSA and methicillin-susceptible S. aureus (MSSA), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group, and vancomycin-susceptible Enterococcus faecalis
- Dalbavancin allows for very convenient parenteral administration, which can be a single dose of 1500 mg or a dose of 1000 mg followed by 500 mg a week later for treating ABSSSI. Dalbavancin is not licensed for use in pediatric patients or for treating BJI, but is potentially important in treating infections due to highly resistant gram-positive cocci (GPC)
- The findings describe dalbavancin *in vitro* activity and potency when tested against a contemporary (2011–2016) collection of GPC isolates responsible for BJI, including osteomyelitis, recovered from adult and pediatric patients in United States (US) medical centers

### **MATERIALS AND METHODS**

#### **Bacterial isolates**

- A total of 744 organisms were evaluated, including 463 S. aureus, 88 coagulase-negative staphylococci (CoNS), 104 BHS, 60 E. faecalis, and 29 viridans group streptococci (VGS)
- Isolates were collected from 55 US medical centers in 2011–2016
- Isolates were determined to be clinically significant based on local guidelines and submitted to a central monitoring laboratory (JMI Laboratories, North Liberty, Iowa, USA) as part of the International Dalbavancin Evaluation of Activity (IDEA) surveillance program
- by the reference monitoring laboratory by standard algorithms and supported by MALDI–TOF–MS (Bruker Daltonics, Bremen, Germany)

#### Antimicrobial susceptibility testing

- Isolates were tested for susceptibility by broth microdilution following guidelines in the CLSI M07–A10 document with testing performed using reference 96-well panels manufactured by JMI Laboratories
- Quality assurance was performed by concurrently testing CLSI-recommended QC reference strains (S. aureus ATCC 29213, E. faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619), and all QC results were within published acceptable ranges
- The dalbavancin breakpoints approved by the Food and Drug Administration (FDA) for indicated species were applied (ie, ≤0.25 µg/mL), and breakpoint criteria for comparator agents were those from CLSI (M100-S27)

# RESULTS

- S. aureus (62.2%) was the most common pathogen associated with BJI, followed by BHS (14.0%) and CoNS (11.8%; Figure 1)
- Dalbavancin inhibited the vast majority of organisms (94.1% of total) at ≤0.06 µg/mL (Figure 2)
- All S. aureus (41.5% MRSA) isolates were susceptible to dalbavancin, linezolid, teicoplanin, and vancomycin, while daptomycin and clindamycin showed susceptibility rates of 99.8% and 87.7% (CLSI), respectively (Table 1)
- Dalbavancin MIC results (MIC<sub>50/00</sub>,  $\leq 0.03/0.06 \ \mu g/mL$ ) were  $\geq 8$ -fold lower compared to daptomycin (MIC<sub>50/00</sub>, 0.25/0.5 µg/mL) against all S. aureus (Table 1)
- Among CoNS (61.4% oxacillin-resistant), dalbavancin (MIC<sub>50/90</sub>,  $\leq 0.03/0.06 \mu g/mL$ ) was the most potent agent, followed by daptomycin (MIC<sub>50/90</sub>, 0.25/0.5 µg/mL), linezolid (MIC<sub>50/90</sub>, 0.5/1 µg/mL), and vancomycin (MIC<sub>50/90</sub>, 1/2 µg/mL; Table 1)

Helio S. Sader, Rodrigo E. Mendes, Robert K. Flamm, Michael A. Pfaller

JMI Laboratories, North Liberty, Iowa, USA

Figure 1. Frequency of occurrence of gram-positive organisms isolated from patients with bone and joint infections in US medical centers



eviations: MSSA, methicillin-susceptible S. aureus: MRSA, methicillin-resistant S. aureus: BHS, B-haemolytic streptococci; CoNS, coagulase-negative staphylococci; and VGS, viridans group streptococo





Abbreviations: MSSA. methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; BHS, β-haemolytic streptococci; CoNS, coagulase-negative staphylococci; and VGS, viridans group streptococc<sup>;</sup>

#### Table 1. Activity of dalbavancin and comparator antimicrobial agents when tested against gram-positive organisms isolated from patients with bone and joint infections from US medical centers

Antmicrobial agent         MC <sub>9</sub> MC <sub>9</sub> %S         %R           S. aureus (463)		MIC <sub>50</sub>	MIC <sub>90</sub>	CLSI <sup>a</sup>		
S. aureus (463)         Dalbavancin $\leq 0.03$ $0.06$ $100.0^{\circ}$ Daptomycin $0.25$ $0.5$ $99.8$ Teicoplanin $\leq 2$ $\leq 2$ $100.0$ $0.0$ Vancomycin       1       1 $100.0$ $0.0$ Unacomycin       1       1 $100.0$ $0.0$ Oxacellin $0.5$ $\geq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $\geq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $\geq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $2.2$ $87.7$ $12.3$ Dalbavancin $50.5$ $s0.5$ $97.2$ $2.8$ CoNS (80)* $$	Antimicrobial agent			%S	%R	
Dailbavancin $\pm 0.03$ $0.06$ $100.0^{\circ}$ Daptornycin $0.25$ $0.5$ $99.8$ Teicoplanin $\leq 2$ $100.0$ $0.0$ Vancomycin         1         1 $100.0$ $0.0$ Linezolid         1         1 $100.0$ $0.0$ Datacomycin $52$ $52.5$ $41.5$ $51.6$ Cilindamycin $50.25$ $>2$ $87.7$ $12.3$ Levofloxacin $0.25$ $>4$ $66.7$ $32.6$ Tetracycline $20.5$ $50.5$ $95.2$ $4.3$ TMP-SMX* $20.5$ $24$ $100.0$ $0.0$ Datbavancin $50.03$ $0.06$ $00.0$ $00.0$ Vancomycin $12$ $100.0$ $0.0$ $00.0$ Vancomycin $12$ $200.0$ $00.0$ $00.0$ Uncomycin $12$ $22$ $38.6$ $614.4$ Clindamycin $20.25$ $>2$ $70.5$ $28.4$	S. aureus (463)					
Daptomycin         0.25         0.5         99.8           Teicoplanin $\leq 2$ $\leq 2$ $100.0$ 0.0           Vancomycin         1         1 $100.0$ 0.0           Linazolid         1         1 $100.0$ 0.0           Oxacillin         0.5 $\geq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $\geq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $\leq 2$ $87.7$ $12.3$ Levofloxacin $0.25$ $\leq 0.5$ $97.2$ $2.8$ CoNS (68) <sup>d</sup> $0.06$ Dabavancin $\leq 0.03$ $0.06$ Vancomycin         1         2 $100.0$ $0.0$ Vancomycin         1         2 $22$ $38.6$ $611.4$ Clindamycin $2.25$ >2 $70.5$ $28.4$ $42.4$ $14.8$ Threacycline $\leq 0.5$ >8 $82.1$ $14.8$ $14.8$	Dalbavancin	≤0.03	0.06	100.0 <sup>b</sup>		
Teicoptanin         ≤2         ≤2         100.0         0.0           Varacomycln         1         1         100.0         0.0           Linezolid         1         1         100.0         0.0           Oxacillin         0.5         >2         58.5         41.5           Clindamycin         ≤0.25         >2         87.7         12.3           Levofloxacin         0.25         >4         66.7         32.6           Tetracycline         ≤0.5         ≤0.5         96.2         4.3           TMP-SMX*         ≤0.5         ≤0.5         97.2         2.8           CoNS (8g)*                Dalbavancin         ≤0.03         0.06              Dalbavancin         0.25         0.5         100.0         0.0            Vancomycln         1         2         100.0         0.0             Vancomycln         1         2         100.0         0.0             Used barancin         0.25         >2         70.5         28.4             Clindamycin	Daptomycin	0.25	0.5	99.8		
Vancomycin         1         1         100.0         0.0           Linezcild         1         1         100.0         0.0           Oxacillin         0.5         >2         58.5         41.5           Clindamycin $< 0.25$ >2         87.7         12.3           Levoftoxacin         0.25         >4         66.7         32.6           Tetracycline $< 0.5$ $< 0.5$ 95.2         4.3           TMP-SMX* $< 0.5$ $< 95.2$ 4.3           TMP-SMX* $< 0.5$ $< 95.2$ 4.3           Dabavancin $< 0.03$ $0.06$ $< 0.01$ Daptomycin $0.25$ $0.5$ $100.0$ $0.0$ Vancomycin $1$ $2$ $100.0$ $0.0$ Vancomycin $2$ > $2$ $38.6$ $61.4$ Clindamycin $< 0.25$ > $2$ $70.5$ $28.4$ Levoftoxacin $0.25$ > $2$ $70.5$ $28.4$ Levoftoxacin $0.25$ > $4$ $69.3$ $30.7$ E. faecalis (6	Teicoplanin	≤2	≤2	100.0	0.0	
Linezolid         1         100.0         0.0           Oxacillin         0.5         >2         58.5         41.5           Clindamycin $s0.5$ >2         87.7         12.3           Levofloxacin         0.25         >4         66.7         32.6           Tetracycline $s0.5$ $s0.5$ 95.2         4.3           TMP-SMX* $s0.5$ $s0.5$ 97.2         2.8           CoNS (88)"	Vancomycin	1	1	100.0	0.0	
Oxacillin0.5>258.541.5Clindamycin50.25>287.712.3Levofloxacin0.25>466.732.6Tetracycline $\leq 0.5$ $\leq 0.5$ 95.24.3TMP-SMX* $\leq 0.5$ $\leq 0.5$ 97.22.8CoNS (88)* $=$ $=$ $=$ $=$ Dalbavancin $\leq 0.03$ $0.06$ $=$ Daptomycin $0.25$ $0.5$ 100.0 $0.0$ Telcoplanin $\leq 2$ 4100.0 $0.0$ Uncorrection $1$ $2$ 100.0 $0.0$ Uncorrection $1$ $2$ 100.0 $0.0$ Uncorrection $0.25$ >270.528.4Clindamycin $\circ 2.5$ >270.528.4Clindamycin $\circ 2.5$ >469.330.7E. faecalic (60) $=$ $=$ $=$ Dalbavancin $0.06$ $0.06$ 95.0*Daptomycin11100.0 $=$ Dalbavancin $0.06$ $0.06$ 95.0*Daptomycin1293.36.7Uncorrection11100.0 $=$ Dalbavancin $0.06$ $0.06$ 95.0*Daptomycin1293.36.7Dalbavancin $0.06$ $0.06$ 95.0*Daptomycin11100.0Tetracycline $> 8$ $> 8$ 25.0 $p$ -naemolytic streptococci (104)* $=$ $=$ Dalbavancin $0.06$ <td>Linezolid</td> <td>1</td> <td>1</td> <td>100.0</td> <td>0.0</td>	Linezolid	1	1	100.0	0.0	
Clindamycin $\leq 0.25$ >2         87.7         12.3           Levofloxacin         0.25         >4         66.7         32.6           Tetracycline $\leq 0.5$ $\leq 0.5$ 95.2         4.3           TMP-SMX* $\leq 0.5$ $\leq 0.5$ 97.2         2.8           Dalbavancin $\leq 0.03$ 0.06	Oxacillin	0.5	>2	58.5	41.5	
Levofioxacin $0.25$ >4 $66.7$ $32.6$ THP-SMX* $50.5$ $50.5$ $95.2$ $4.3$ TMP-SMX* $50.5$ $97.2$ $2.8$ CoNS (88)"	Clindamycin	≤0.25	>2	87.7	12.3	
Tetracycline $\le 0.5$ $\le 0.5$ $\le 95.2$ $4.3$ TMP-SMX° $\le 0.5$ $\le 97.2$ $2.8$ CoNS (88) <sup>a</sup> $=$ $=$ $=$ Dalbavancin $\le 0.03$ $0.06$ $=$ Daptomycin $0.25$ $0.5$ $100.0$ $0.0$ Varcomycin         1         2 $100.0$ $0.0$ Uncomycin         1         2 $100.0$ $0.0$ Uncomycin         1         2 $100.0$ $0.0$ Oxacillin         2         >2 $38.6$ $61.4$ Clindamycin $\le0.25$ >2 $70.5$ $28.4$ Levolloxacin $0.25$ >4 $59.1$ $36.4$ Tetracycline $\le0.5$ >4 $68.3$ $30.7$ <i>E. faecalis</i> (60) $=$ $=$ $=$ $=$ Dalbavancin $0.06$ $0.95.0^{\circ}$ $=$ $=$ Dalbavancin $1$ $1$ $100.0$ $0.0$ Amcomyc	Levofloxacin	0.25	>4	66.7	32.6	
TMP-SMX°         ≤0.5         ≤0.5         97.2         2.8           CoNS (88)°	Tetracycline	≤0.5	≤0.5	95.2	4.3	
CoNS (88) <sup>a</sup> Second Sec	TMP-SMX <sup>c</sup>	≤0.5	≤0.5	97.2	2.8	
Dalbavancin $\leq 0.03$ 0.06            Daptomycin         0.25         0.5         100.0	CoNS (88) <sup>d</sup>					
Daptomycin         0.25         0.5         100.0           Teicoplanin $\leq 2$ 4         100.0         0.0           Vancomycin         1         2         100.0         0.0           Linezolid         0.5         1         100.0         0.0           Oxacillin         2         >2         38.6         61.4           Clindamycin $\leq 0.25$ >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline $\leq 0.5$ >8         84.1         14.8           TMP-SMX° $\leq 0.5$ >4         69.3         30.7 <i>E. faecalis</i> (60)	Dalbavancin	≤0.03	0.06			
Teicoplanin         ≤2         4         100.0         0.0           Vancomycin         1         2         100.0         0.0           Linezolid         0.5         1         100.0         0.0           Oxacillin         2         >2         38.6         61.4           Clindamycin         ≤0.25         >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline         ≤0.5         >4         69.3         30.7 <i>E. faecalis</i> (60)           95.0°            Dalbavancin         0.06         0.06         95.0°            Datomycin         1         1         100.0            Teicoplanin         ≤2         ≤2         93.3         6.7           Linezolid         1         1         100.0         0.0           Ametoilin         1         1         100.0         0.0           Ametoilin         1         1         100.0         0.0           Ametoilin         1         1         100.0         0.0           Ampicillin         1         1         <	Daptomycin	0.25	0.5	100.0		
Vancomycin         1         2         100.0         0.0           Linezolid         0.5         1         100.0         0.0           Oxacillin         2         >2         38.6         61.4           Clindamycin $\leq 0.25$ >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline $\leq 0.5$ >8         84.1         14.8           TMP-SMX° $\leq 0.5$ >4         69.3         30.7           E. faecalis (60)         0.06         95.0°	Teicoplanin	≤2	4	100.0	0.0	
Linezolid         0.5         1         100.0         0.0           Oxacillin         2         >2         38.6         61.4           Clindamycin         ≤0.25         >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline         ≤0.5         >8         84.1         14.8           TMP-SMX°         ≤0.5         >4         69.3         30.7 <i>E. faecalis</i> (60)	Vancomycin	1	2	100.0	0.0	
Oxacillin         2         >2         38.6         61.4           Clindamycin         ≤0.25         >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline         ≤0.5         >8         84.1         14.8           TMP-SMX°         ≤0.5         >4         69.3         30.7 <i>E faecalis</i> (60)               Dalbavancin         0.06         0.06         95.0°            Daptomycin         1         1         100.0             Teicoplanin         ≤2         ≤2         93.3         6.7            Vancomycin         1         2         93.3         6.7            Vancomycin         1         2         93.3         6.7            Linezolid         1         1         100.0         0.0             Levofloxacin         1         2         93.3         6.7             Levofloxacin         1         1         100.0              Dalbavancin	Linezolid	0.5	1	100.0	0.0	
Clindamycin         ≤0.25         >2         70.5         28.4           Levofloxacin         0.25         >4         59.1         36.4           Tetracycline         ≤0.5         >8         84.1         14.8           TMP-SMX°         ≤0.5         >4         69.3         30.7 <i>E. faecalis</i> (60)           95.0°            Dabavancin         0.06         0.06         95.0°            Daptomycin         1         1         100.0            Teicoplanin         ≤2         ≤2         93.3         6.7           Vancomycin         1         2         93.3         6.7           Linezolid         1         100.0         0.0            Ampicillin         1         1         100.0         0.0           Ampicillin         1         1         98.3         1.7           Levofloxacin         1         >4         71.7         28.3           Tetracycline         >8         >8         25.0         73.3           β-haemolytic streptococci (104)*           100.0            Dalbavancin         0.12	Oxacillin	2	>2	38.6	61.4	
Levofloxacin         0.25         >4         59.1         36.4           Tetracycline         ≤0.5         >8         84.1         14.8           TMP-SMX*         ≤0.5         >4         69.3         30.7 <i>E. faecalis</i> (60)            50.9           Dalbavancin         0.06         0.06         95.0°            Dabornycin         1         1         100.0            Teicoplanin         ≤2         ≤2         93.3         6.7           Vancomycin         1         2         93.3         6.7           Linezolid         1         100.0         0.0         0.0           Ampicillin         1         100.0         0.0         0.0           Ampicillin         1         1         98.3         1.7           Levofloxacin         1         >4         71.7         28.3           Tetracycline         >8         >8         25.0         73.3           β-haemolytic streptococci (104)*          0.025         100.0            Dalbavancin         0.12         0.25         100.0             Vancomycin <td>Clindamycin</td> <td>≤0.25</td> <td>&gt;2</td> <td>70.5</td> <td>28.4</td>	Clindamycin	≤0.25	>2	70.5	28.4	
Tetracycline         ≤0.5         >8         84.1         14.8           TMP-SMX°         ≤0.5         >4         69.3         30.7           E. faecalis (60)                Dalbavancin         0.06         0.06         95.0°             Daptomycin         1         1         100.0              Teicoplanin         ≤2         ≤2         93.3         6.7 <t< td=""><td>Levofloxacin</td><td>0.25</td><td>&gt;4</td><td>59.1</td><td>36.4</td></t<>	Levofloxacin	0.25	>4	59.1	36.4	
TMP-SMX°         ≤0.5         >4         69.3         30.7           E. faecalis (60)         Dalbavancin         0.06 $95.0^{\circ}$ Daptomycin         1         1         100.0            Telcoplanin         ≤2         ≤2 $93.3$ $6.7$ Vancomycin         1         2 $93.3$ $6.7$ Vancomycin         1         2 $93.3$ $6.7$ Linezolid         1         1         100.0 $0.0$ Ampicillin         1         1 $98.3$ $1.7$ Levofloxacin         1         >4 $71.7$ $28.3$ Tetracycline         >8         >8 $25.0$ $73.3$ β-haemolytic streptococci (104)° $0.03$ $100.0^{\circ}$ Dalbavancin         ≤0.03 $100.0^{\circ}$ $0.05$ $100.0$ Vancomycin         0.12         0.25 $100.0$ $0.06$ $0.00$ Dalbavancin         ≤0.06         0.12 $100.0$ $0.06$ $23.3$ $1.9$ </td <td>Tetracycline</td> <td>≤0.5</td> <td>&gt;8</td> <td>84.1</td> <td>14.8</td>	Tetracycline	≤0.5	>8	84.1	14.8	
E. faecalis (60)         Dalbavancin       0.06       0.06       95.0 <sup>b</sup> Daptomycin       1       1       100.0         Teicoplanin       ≤2       ≤2       93.3       6.7         Vancomycin       1       2       93.3       6.7         Linezolid       1       1       100.0       0.0         Ampicillin       1       1       98.3       1.7         Levofloxacin       1       >4       71.7       28.3         Tetracycline       >8       >8       25.0       73.3         β-haemolytic streptococci (104) <sup>e</sup> U       U       U       U         Dalbavancin       ≤0.03       ≤0.03       100.0 <sup>b</sup> U         Daptomycin       0.12       0.25       100.0       U         Vancomycin       0.25       0.5       100.0       U         Question       ≤0.06       0.12       100.0       U         Ceftriaxone       ≤0.06       0.12       100.0       U         Clindamycin       ≤0.25       >2       76.7       23.3         Levofloxacin       0.5       1       98.1       1.9       1.9         Tetracyc	TMP-SMX <sup>c</sup>	≤0.5	>4	69.3	30.7	
Dalbavancin         0.06         0.06         95.0 <sup>b</sup> Daptomycin         1         1         100.0           Teicoplanin         ≤2         ≤2         93.3         6.7           Vancomycin         1         2         93.3         6.7           Linezolid         1         1         100.0         0.0           Ampicillin         1         1         100.0         0.0           Ampicillin         1         1         98.3         1.7           Levofloxacin         1         >4         71.7         28.3           Tetracycline         >8         >8         25.0         73.3           β-haemolytic streptococci (104)e               Dalbavancin         ≤0.03         ≤0.03         100.0 <sup>b</sup> Daptomycin         0.12         0.25         100.0             Vancomycin         0.25         0.5         100.0             Vancomycin         0.25         >2         76.7         23.3            Clindamycin         ≤0.05         1         98.1         1.9           Clindamycin	E. faecalis (60)	1	I			
Daptomycin         1         1         100.0           Teicoplanin         ≤2         ≤2         93.3         6.7           Vancomycin         1         2         93.3         6.7           Linezolid         1         100.0         0.0           Ampicillin         1         100.0         0.0           Ampicillin         1         100.0         0.0           Ampicillin         1         98.3         1.7           Levofloxacin         1         >4         71.7         28.3           Tetracycline         >8         >8         25.0         73.3           β-haemolytic streptococt (104)e               Dalbavancin         ≤0.03         ≤0.03         100.0 <sup>b</sup> Daptomycin         0.12         0.25         100.0              Vancomycin         0.25         0.5         100.0               Vancomycin         0.25         >2         76.7         23.3             Celtriaxone         ≤0.06         0.12         100.0 <td< td=""><td>Dalbavancin</td><td>0.06</td><td>0.06</td><td>95.0<sup>b</sup></td><td></td></td<>	Dalbavancin	0.06	0.06	95.0 <sup>b</sup>		
Teicoplanin         ≤2         ≤2         93.3         6.7           Vancomycin         1         2         93.3         6.7           Linezolid         1         100.0         0.0           Ampicillin         1         100.0         0.0           Ampicillin         1         198.3         1.7           Levofloxacin         1         >4         71.7         28.3           Tetracycline         >8         >8         25.0         73.3           β-haemolytic streptococci (104)e               Dalbavancin         ≤0.03         ≤0.03         100.0b             Vancomycin         0.12         0.25         100.0             Vancomycin         0.25         0.5         100.0             Linezolid         1         1         100.0             Ceftriaxone         ≤0.06         0.12         100.0             Clindamycin         ≤0.25         >2         76.7         23.3            Levofloxacin         0.5         1         98.1         1.9 </td <td>Daptomycin</td> <td>1</td> <td>1</td> <td>100.0</td> <td></td>	Daptomycin	1	1	100.0		
Vancomycin1293.36.7Linezolid11100.00.0Ampicillin1198.31.7Levofloxacin1>471.728.3Tetracycline>8>825.073.3β-haemolytic streptococci (104)° $\sim$ $\sim$ $\sim$ Dalbavancin≤0.03≤0.03100.0° $\sim$ Daptomycin0.120.25100.0 $\sim$ Vancomycin0.250.5100.0 $\sim$ Linezolid11100.0 $\sim$ Ceftriaxone≤0.060.12100.0 $\sim$ Clindamycin≤0.25>276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococci (29) $\sim$ $\sim$ $\sim$ Dalbavancin≤0.030.06100.0°	Teicoplanin	≤2	≤2	93.3	6.7	
Linezolid11100.00.0Ampicillin1198.31.7Levofloxacin1>471.728.3Tetracycline>8>825.073.3β-haemolytic streptococci (104)* $>$ $>$ $20.03$ 100.0*Dalbavancin $\leq 0.03$ $\leq 0.03$ 100.0* $<$ Daptomycin0.120.25100.0 $<$ Vancomycin0.250.5100.0 $<$ Linezolid11100.0 $<$ Ceftriaxone $\leq 0.06$ 0.12100.0 $<$ Clindamycin $\leq 0.25$ >276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococci (29) $\leq 0.03$ 0.06100.0*	Vancomycin	1	2	93.3	6.7	
Ampicillin1198.31.7Levofloxacin1>471.728.3Tetracycline>8>825.073.3β-haemolytic streptococci (104)° $\leq 0.03$ $\leq 0.03$ 100.0°Dalbavancin $\leq 0.03$ $\leq 0.03$ 100.0°Daptomycin0.120.25100.0Vancomycin0.250.5100.0Linezolid11100.0Penicillin $\leq 0.06$ $\leq 0.06$ 100.0Ceftriaxone $\leq 0.06$ 0.12100.0Clindamycin $\leq 0.25$ >276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococci (29) $\leq 0.03$ 0.06100.0°	Linezolid	1	1	100.0	0.0	
Levofloxacin1>471.728.3Tetracycline>8>825.073.3β-haemolytic streptococci (104)°Dalbavancin≤0.03≤0.03100.0°Daptomycin0.120.25100.0Vancomycin0.250.5100.0Uinezolid1100.0Linezolid1100.0Ceftriaxone≤0.060.12100.0Clindamycin≤0.25>276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococci (29)©.030.06100.0°	Ampicillin	1	1	98.3	1.7	
Tetracycline>8>825.073.3β-haemolytic streptococci (104)°Dalbavancin $\leq 0.03$ $\leq 0.03$ $100.0^{\circ}$ Daptomycin0.120.25 $100.0$ Vancomycin0.250.5 $100.0$ Linezolid11 $100.0$ Penicillin $\leq 0.06$ $\leq 0.06$ $100.0$ Ceftriaxone $\leq 0.06$ $0.12$ $100.0$ Clindamycin $\leq 0.25$ >2 $76.7$ $23.3$ Levofloxacin $0.5$ 1 $98.1$ $1.9$ Tetracycline>8>8 $41.3$ $55.8$ Viridans group streptococci (29) $0.06$ $100.0^{\circ}$	Levofloxacin	1	>4	71.7	28.3	
β-haemolytic streptococci (104)°Dalbavancin $\leq 0.03$ $\leq 0.03$ $100.0^b$ Daptomycin0.120.25100.0Vancomycin0.250.5100.0Linezolid11100.0Penicillin $\leq 0.06$ $\leq 0.06$ 100.0Ceftriaxone $\leq 0.06$ 0.12100.0Clindamycin $\leq 0.25$ >276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococci (29)Dalbavancin $\leq 0.03$ 0.06100.0 <sup>b</sup>	Tetracycline	>8	>8	25.0	73.3	
Dalbavancin $\leq 0.03$ $\leq 0.03$ $100.0^{\circ}$ Daptomycin0.120.25100.0Vancomycin0.250.5100.0Linezolid11100.0Penicillin $\leq 0.06$ $\leq 0.06$ 100.0Ceftriaxone $\leq 0.06$ 0.12100.0Clindamycin $\leq 0.25$ >276.7Clindamycin $\leq 0.25$ 198.1Tetracycline>8>841.3Viridans group streptococci (29)0.06100.0^{\circ}	β-haemolytic streptococci (104) <sup>e</sup>					
Daptomycin         0.12         0.25         100.0           Vancomycin         0.25         0.5         100.0           Linezolid         1         1         100.0           Penicillin         ≤0.06         ≤0.06         100.0           Ceftriaxone         ≤0.06         0.12         100.0           Clindamycin         ≤0.25         >2         76.7         23.3           Levofloxacin         0.5         1         98.1         1.9           Tetracycline         >8         >8         41.3         55.8           Viridans group streptococci (29)         0.06         100.0 <sup>b</sup>	Dalbavancin	≤0.03	≤0.03	100.0 <sup>b</sup>		
Vancomycin $0.25$ $0.5$ $100.0$ Linezolid11 $100.0$ Penicillin $\leq 0.06$ $\leq 0.06$ $100.0$ Ceftriaxone $\leq 0.06$ $0.12$ $100.0$ Clindamycin $\leq 0.25$ >2 $76.7$ $23.3$ Levofloxacin $0.5$ 1 $98.1$ $1.9$ Tetracycline>8>8 $41.3$ $55.8$ Viridans group streptococci (29) $0.03$ $0.06$ $100.0^{b}$	Daptomycin	0.12	0.25	100.0		
Linezolid         1         100.0           Penicillin         ≤0.06         100.0           Ceftriaxone         ≤0.06         0.12         100.0           Clindamycin         ≤0.25         >2         76.7         23.3           Levofloxacin         0.5         1         98.1         1.9           Tetracycline         >8         >8         41.3         55.8           Viridans group streptoccci (29)         0.06         100.0 <sup>b</sup> 100.0 <sup>b</sup>	Vancomycin	0.25	0.5	100.0		
Penicillin $\leq 0.06$ $\leq 0.06$ 100.0Ceftriaxone $\leq 0.06$ 0.12100.0Clindamycin $\leq 0.25$ >276.723.3Levofloxacin0.5198.11.9Tetracycline>8>841.355.8Viridans group streptococi (29)Dalbavancin $\leq 0.03$ 0.06100.0b	Linezolid	1	1	100.0		
Ceftriaxone         ≤0.06         0.12         100.0           Clindamycin         ≤0.25         >2         76.7         23.3           Levofloxacin         0.5         1         98.1         1.9           Tetracycline         >8         >8         41.3         55.8           Viridans group streptococci (29)         0.06         100.0 <sup>b</sup> 100.0 <sup>b</sup>	Penicillin	≤0.06	≤0.06	100.0		
Clindamycin         ≤0.25         >2         76.7         23.3           Levofloxacin         0.5         1         98.1         1.9           Tetracycline         >8         >8         41.3         55.8           Viridans group streptococci (29)         0.06         100.0 <sup>b</sup> 100.0 <sup>b</sup>	Ceftriaxone	≤0.06	0.12	100.0		
Levofloxacin         0.5         1         98.1         1.9           Tetracycline         >8         >8         41.3         55.8           Viridans group streptococci (29)          0.06         100.0 <sup>b</sup>	Clindamycin	≤0.25	>2	76.7	23.3	
Tetracycline         >8         41.3         55.8           Viridans group streptococci (29)         50.03         0.06         100.0 <sup>b</sup>	Levofloxacin	0.5	1	98.1	1.9	
Viridans group streptococci (29)Dalbavancin≤0.030.06100.0 <sup>b</sup>	Tetracycline	>8	>8	41.3	55.8	
Dalbavancin ≤0.03 0.06 100.0 <sup>b</sup>	Viridans group streptoc	occi (29)	1			
	Dalbavancin	≤0.03	0.06	100.0 <sup>b</sup>		
Daptomycin 0.5 1 100.0	Daptomycin	0.5	1	100.0		
Vancomycin 0.5 1 100.0	Vancomycin	0.5	1	100.0		
Linezolid 1 1 100.0	Linezolid	1	1	100.0		
Penicillin ≤0.06 2 79.3 3.4	Penicillin	≤0.06	2	79.3	3.4	
Ceftriaxone         0.12         1         93.1         0.0	Ceftriaxone	0.12	1	93.1	0.0	
Clindamycin ≤0.25 >2 82.8 17.2	Clindamvcin	≤0.25	>2	82.8	17.2	
Levofloxacin 1 2 93.1 3.4	Levofloxacin	1	2	93.1	3.4	
Tetracycline         1         >8         58.6         37.9	Tetracycline	1	>8	58.6	37.9	

<sup>a</sup> Criteria as published by CLSI [2017]

<sup>b</sup> Breakpoints from FDA Package Insert applied for all *E. faecalis*, but approved for vancomycin-susceptible isolates only

<sup>c</sup> TMP-SMX, trimethoprim-sulfamethoxazole

Organisms include Staphylococcus capitis (1), S. caprae (5), S. cohnii (1), S. epidermidis (49), S. haemolyticus (3), S. hominis (4), S. lugdunensis (16), S. pettenkoferi (1), S. pseudintermedius (1), S. simulans (2), S. warneri (3), unspeciated coagulase-negative staphylococci (2)

<sup>e</sup> Organisms include Streptococcus agalactiae (60), S. dysgalactiae (18), S. pyogenes (26)

Contact Information: Helio S. Sader, MD, PhD JMI Laboratories 345 Beaver Kreek Centre, Suite A North Liberty, IA 52317 Phone: (319) 665-3370 Fax: (319) 665-3371 Email: helio-sader@jmilabs.com



To obtain a PDF of this poster: Scan the QR code

Visit www.allergancongressposters.com/168310

Charges may apply. No personal information is stored.

- Dalbavancin inhibited 95.0% of *E. faecalis* isolates at ≤0.25 µg/mL (FDA susceptible breakpoint); only 3 vancomycin-resistant (VanA) isolates exhibited elevated dalbavancin MIC values with all 3 at >2 µg/mL (Figure 2 and Table 1)
- High susceptibility rates for ampicillin (98.3%; CLSI), daptomycin (100.0%), linezolid (100.0%), teicoplanin (93.3%), and vancomycin (93.3%) were obtained against *E. faecalis* (Table 1)
- Dalbavancin, daptomycin, linezolid, ceftriaxone, penicillin, and vancomycin were active against all BHS (100.0% susceptible; Table 1)
- Dalbavancin (MIC<sub>50/90</sub>, ≤0.03/0.06 µg/mL; 100.0% susceptible) was the most active agent against VGS, inhibiting all isolates at  $\leq 0.06 \ \mu g/mL$  (Table 1)
- Ceftriaxone, levofloxacin, linezolid, daptomycin, and vancomycin were also active against VGS (93.1%– 100.0% susceptible per CLSI), whereas clindamycin (82.8% susceptible) had marginal activity (Table 1)

### CONCLUSIONS

- S. aureus isolates were the most frequent pathogens responsible for BJI in this study population; a total of 41.5% of these isolates were methicillin-resistant, which precludes using both commonly used antimicrobial therapies, cefazolin and oxacillin, for such cases
- Dalbavancin demonstrated potent in vitro activity against common gram-positive isolates causing BJI in the US (2011–2016)
- This *in vitro* characteristic along with prolonged half-life and convenient administration make dalbavancin a promising candidate for treating BJI, including osteomyelitis caused by gram-positive cocci

# ACKNOWLEDGEMENTS

This study was supported by Allergan. Allergan was involved in the design and decision to present these results, and JMI Laboratories received compensation for services in relation to preparing this presentation. Allergan had no involvement in the collection, analysis, or interpretation of data.

#### REFERENCES

- Barnea Y, Lerner A, Aizic A, et al. (2016). Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. *J Antimicrob Chemother* 71: 460-463.
- Boucher HW, Wilcox M, Talbot GH, et al. (2014). Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370: 2169-2179.
- 5. Chiappini E, Mastrangelo G, Lazzeri S (2016). A case of acute osteomyelitis: An update on diagnosis and treatment. Int J Environ Res Public Health 13: E539.
- Clinical and Laboratory Standards Institute (2015). M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—tenth edition. Wayne, PA: CLSI.
- Clinical and Laboratory Standards Institute (2017). M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Wayne, PA: CLSI.
- 6. Dalvance<sup>™</sup> Package Insert (2016). Available at http://www.allergan.com/assets/pdf/dalvance pi. Accessed March 2017.
- EUCAST (2017). Breakpoint tables for interpretation of MIC's and zone diameters. Version 7.1, March 2017. Available at http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\_files/Breakpoint \_tables/v\_7.1\_Breakpoint\_Tables.pdf. Accessed March 2017.
- 8. Garnock-Jones KP (2017). Single-dose dalbavancin: A review in acute bacterial skin and skin structure infections. Drugs 77: 75-83.
- 9. Maffulli N, Papalia R, Zampogna B, et al. (2016). The management of osteomyelitis in the adult. *Surgeon* 14: 345-360.
- 10. Mendes RE, Castanheira M, Farrell DJ, et al. (2016). Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). *J Antimicrob Chemother* 71: 276-278.